Gene Therapy Drama: 2nd Elevidys Death

Big news in the gene therapy world: another patient has died after getting Sarepta’s Elevidys for Duchenne muscular dystrophy, again due to acute liver failure—a known risk with these treatments. Sarepta’s now pausing shipments for non-ambulatory patients and putting new safety steps in place, including possibly adding another immunosuppressant. Investors are spooked, and there’s talk about whether Elevidys could get pulled for some patients. The whole gene therapy field is feeling the heat right now! #GeneTherapy #Elevidys #DMD #Health #BodyHealth